<DOC>
	<DOCNO>NCT00526071</DOCNO>
	<brief_summary>This long term open label study AT1001 patient Fabry disease previously enrol Phase 2 AT1001 trial .</brief_summary>
	<brief_title>Open Label Long-term Safety Study AT1001 Patients With Fabry Disease Who Have Completed Previous AT1001 Study</brief_title>
	<detailed_description>This long term open label study AT1001 patient Fabry disease previously enrol Phase 2 AT1001 trial . Patients return study center approximately every 3 month safety evaluation include physical exam , blood urine test .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>1 . Must complete another Phase 2 trial AT1001 Fabry Disease 2 . Women childbearing potential must negative pregnancy result 3 . Male Female subject agree use reliable method contraception treatment four week treatment complete . 4 . Subject willing able provide write informed consent 1 . Subject complete Phase 2 trial AT1001 Fabry Disease 2 . Has undergone schedule undergo kidney transplantation currently dialysis 3 . Has treat another investigational drug ( except AT1001 ) within 30 day study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Fabry Disease</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
</DOC>